Amira Therapeutics SL has announced new preclinical findings for its lead compound AMI-463, which is being developed primarily for rhabdomyosarcoma, the most common soft tissue sarcoma in children.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback